Navigation Links
Alexza Pharmaceuticals Reports 2010 Third Quarter Financial Results and Provides Business Update
Date:11/9/2010

w.alexza.com/about/the-staccato-system/staccato-animation">here to see an animation of how the Staccato system works.)

AZ-004 (Staccato loxapine) is Alexza's lead program, which is being developed for the rapid treatment of agitation in schizophrenic or bipolar disorder patients. Alexza has completed and announced positive results from both of its AZ-004 Phase 3 clinical trials and submitted a New Drug Application (NDA) in December 2009.  In October 2010, the Company received a CRL from the FDA, regarding its NDA for AZ-004.  A CRL is issued by FDA's Center for Drug Evaluation and Research indicating that the NDA review cycle is complete and the application is not ready for approval in its present form.  The Company is currently evaluating the FDA's comments in the CRL and anticipates meeting with the FDA in the fourth quarter of 2010 to discuss the CRL.

For more information about Alexza, the Staccato technology or the Company's development programs, please visit www.alexza.com.

Safe Harbor Statement

Alexza's policy is to only provide guidance on product candidates and corporate goals for the future one to two fiscal quarters, and to provide, update or reconfirm its guidance only by issuing a press release or filing updated guidance with the SEC in a publicly accessible document.  The Company's guidance in this release is as of November 9, 2010 and financial guidance relating to the Company's current cash, cash equivalents and investments is as of September 30, 2010.

This news release contains forward-looking statements that involve significant risks and uncertainties, including our ability to establish a path for AZ-004 approval after meeting with the FDA. Any statement describing the Company's expectations or beliefs is a forward-looking statement, as defined in the Private Securities Litigation Reform Act of 1995, and should be co
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients
2. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
3. Alexzas AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache
4. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
5. Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon)
6. Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients
7. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
8. Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder
9. Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation
10. Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting
11. Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... 2015  Growth of the U.S. nonprescription market is ... prescription users to the OTC market. Due to an ... Rx-to-OTC switch activity over the next five years with ... new brands entering the market into existing categories. ... years (even those with low to moderate likelihood), the ...
(Date:7/30/2015)... 30, 2015  Medimetriks Pharmaceuticals, Inc. announced today ... III clinical study for Ozenoxacin, a novel bactericidal ... the exclusive U.S. rights to Ozenoxacin 1% cream.  ... 44 centers with an emphasis on U.S. patients, ... months and older with a clinical diagnosis of ...
(Date:7/30/2015)... 2015 Vermillion, Inc. (VRML), a ... announced today it will report its second ... close on Thursday, August 13, 2015, followed ... at 4:30pm Eastern.Conference Call and Webcast:  ... Pacific  Domestic: , 888-430-8691International: ...
Breaking Medicine Technology:Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 2Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 3Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 2Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 3
(Date:7/30/2015)... ... July 30, 2015 , ... Eyepartner is proud ... in San Diego, California’s Gaslamp Quarter Plaza for five years this September. , ... monitor the area for any suspicious activity. These cameras are in place to ...
(Date:7/30/2015)... ... July 30, 2015 , ... " DevExpress ” ... a look at small, medium, and large businesses making an impact in their ... business review and shared with viewers how DevExpress has provided software development tools ...
(Date:7/30/2015)... ... July 30, 2015 , ... The Beryl ... Scholar Program. In partnership with Patient Experience Institute, these offerings reinforce the commitment ... the front lines and throughout the experience movement, and provide information and research ...
(Date:7/30/2015)... , ... July 30, 2015 , ... ... today that the latest issue of Inclusive™ magazine, its multimedia publication focused on ... digital edition of the new issue, Volume 6, Issue 2, as well as ...
(Date:7/30/2015)... ... July 30, 2015 , ... Between 2012 and 2014 HIV ... Health News Florida on June 17th. Those untreated heroin use disorders share their ... the spread of dirty needles throughout the community. Ultimately Florida’s HIV infection rates have ...
Breaking Medicine News(10 mins):Health News:Eyepartner Software Helps Victims in Gaslamp Quarter Plaza 2Health News:Eyepartner Software Helps Victims in Gaslamp Quarter Plaza 3Health News:Software to Develop High-Performance Data-Driven Apps was Featured on NewsWatch Television 2Health News:The Beryl Institute Opens Applications for 2015 Patient Experience Grant and Scholar Programs 2Health News:The Beryl Institute Opens Applications for 2015 Patient Experience Grant and Scholar Programs 3Health News:Glidewell Laboratories Puts Out Latest Issue of Dental Implant Magazine Inclusive™ 2Health News:Glidewell Laboratories Puts Out Latest Issue of Dental Implant Magazine Inclusive™ 3Health News:Glidewell Laboratories Puts Out Latest Issue of Dental Implant Magazine Inclusive™ 4Health News:HIV Rates Rise in S. Florida, Harbor Village Comments on Health News Florida's Recent Article 2Health News:HIV Rates Rise in S. Florida, Harbor Village Comments on Health News Florida's Recent Article 3
... The naturally high levels of leptin in diabetic patients ... treat heart blockages, but using a chemical that differs ... counteract this effect. , The work by researchers at ... diabetics who get stents, they say. Though drug-eluting stents ...
... Pheromone,Sciences, Inc. (OTC Bulletin Board: EROX) ("HPS" or "the ... with the U.S. Patent and,Trademark Office for the use ... in sea coral, which has significant emotional impacts,on both ... well-being and social attraction. , ...
... United Health Foundation announced its commitment to American Indian ... Indian Country by donating $45,000 for nine $5,000 scholarships ... support of Arizona students pursuing careers in the health ... scholarship recipients were chosen based on their academic achievement, ...
... SACRAMENTO, Calif., Dec. 17 Sutter Health has announced,the ... general,counsel. She will assume her new role January 5, ... , Formerly senior ... Eisenbeis, LLP (HRDE) for the past two decades, DiBenedetto,served ...
... Hospital have answered a central question in cancer biology: ... Stem cells are immature cells that can renew themselves ... the range of body tissues. In recent years, researchers ... forms of stem cells. , Like a brand-name ...
... Combines ZEISS,s Precision Progressive Lenses and Transitions® Lenses to Produce Optimal ... ... 17, 2008 -- Two of the most distinguished names in the ... leading-edge eyewear., , ,Carl Zeiss Vision, a leader for 160 years ...
Cached Medicine News:Health News:HPS Files Patent for Mood-Enhancing Compound Naturally Found in Sea Coral 2Health News:United Health Foundation Provides $45,000 for Scholarships to the American Indian College Fund for Arizona Healthcare Students 2Health News:United Health Foundation Provides $45,000 for Scholarships to the American Indian College Fund for Arizona Healthcare Students 3Health News:Sutter Health Welcomes New General Counsel 2Health News:Molecular marker identifies normal stem cells as intestinal tumor source 2Health News:Carl Zeiss Vision and Transitions Optical Inc. Promote Pioneering Eyewear to Consumers 2
... up to 10 inches/ 25 cm thinner than other ... Allegra X-22 Series is the space-saving multipurpose solution for ... / 46 cm wide • 11 Rotor Library • ... ways to Spin 1.5 mL & PCR+ Tubes: ...
... is up to 10 inches/ 25 cm thinner than ... the Allegra X-22 Series is the space-saving multipurpose solution ... inches / 46 cm wide • 11 Rotor Library ... different ways to Spin 1.5 mL & PCR+ Tubes: ...
... centrifuges offer high-volume versatility along with a ... them ideal for a wide variety of ... Four- or six-place sealed swinging bucket rotor, ... offered , Lare capacity (4 x 750 ...
... Multipurpose high performance centrifuge designed to accommodate ... devices is refrigerated for heat labile samples. ... include refrigerated capability with automatic quick cooling ... < 7 min, no maintenance brushless motor, ...
Medicine Products: